SCHEMBL8809278

SCHEMBL8809278

CC(C)Cc1nc2cc(N)ccc2[nH]1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.75
KDM4E B2RXH2 3/20 0.75
PKM P14618 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 4/20 0.42
LMNA P02545 3/20 0.42
NPC1 O15118 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
RAD52 P43351 1/20 0.42
MAPKAPK2 P49137 1/20 0.41
RPS6KA3 P51812 1/20 0.41
CSNK2A1 P68400 1/20 0.41
PLK3 Q9H4B4 1/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25160282 0.82 MAPT (0.55) MAPTKDM4ETDP1KMT2AMEN1
SCHEMBL18656067 0.82 MAPT (0.55) MAPTKDM4ETDP1KMT2AMEN1
SCHEMBL7029404 0.81 DDAH1 (0.58) MAPTKDM4EPKMTDP1KMT2A
SCHEMBL23793903 0.81 MAPT (0.55) MAPTKDM4EPKMTDP1KMT2A
SCHEMBL8229333 0.81 MAPT (0.54) MAPTKDM4ETDP1KMT2AMEN1
SCHEMBL6755178 0.80 MAPT (0.61) MAPTKDM4EPKMTDP1KMT2A
SCHEMBL8807127 0.79 MAPT (0.55) MAPTKDM4EPKMTDP1KMT2A
SCHEMBL4241945 0.78 MAPT (0.51) MAPTKDM4ETDP1KMT2AMEN1
SCHEMBL3947749 0.78 RAD52 (0.53) MAPTKDM4EPKMTDP1KMT2A
SCHEMBL10289499 0.78 MAPT (0.50) MAPTKDM4EPKMTDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272617-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-22 US disclosed
EP-0775134-A4 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMA CORP (US) 1997-08-13 EP disclosed
EP-0775134-A1 Imidazolin-2-ylaminobenzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-05-28 EP disclosed
WO-1996004270-A1 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1996-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272617-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES PAH, PEPD, AADAT MAPT 2938/4885KDM4E 1094/4885PKM 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.